- Home
- INO vs IGA Comparison
INO vs IGA Comparison
Compare INO & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- IGA
- Stock Information
- Founded
- INO 1979
- IGA 2005
- Country
- INO United States
- IGA United States
- Employees
- INO 134
- IGA N/A
- Industry
- INO Medical/Dental Instruments
- IGA Investment Managers
- Sector
- INO Health Care
- IGA Finance
- Exchange
- INO Nasdaq
- IGA Nasdaq
- Market Cap
- INO 128.1M
- IGA 151.6M
- IPO Year
- INO 1998
- IGA N/A
- Fundamental
- Price
- INO $2.37
- IGA $9.88
- Analyst Decision
- INO Buy
- IGA
- Analyst Count
- INO 5
- IGA 0
- Target Price
- INO $8.80
- IGA N/A
- AVG Volume (30 Days)
- INO 1.1M
- IGA 42.3K
- Earning Date
- INO 11-13-2025
- IGA 01-01-0001
- Dividend Yield
- INO N/A
- IGA 8.93%
- EPS Growth
- INO N/A
- IGA N/A
- EPS
- INO N/A
- IGA N/A
- Revenue
- INO $182,337.00
- IGA N/A
- Revenue This Year
- INO N/A
- IGA N/A
- Revenue Next Year
- INO $15,960.33
- IGA N/A
- P/E Ratio
- INO N/A
- IGA N/A
- Revenue Growth
- INO N/A
- IGA N/A
- 52 Week Low
- INO $1.30
- IGA $7.77
- 52 Week High
- INO $5.83
- IGA $8.88
- Technical
- Relative Strength Index (RSI)
- INO 54.07
- IGA 49.62
- Support Level
- INO $2.38
- IGA $9.77
- Resistance Level
- INO $2.58
- IGA $9.94
- Average True Range (ATR)
- INO 0.14
- IGA 0.08
- MACD
- INO -0.03
- IGA -0.01
- Stochastic Oscillator
- INO 51.95
- IGA 41.98
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.